The developed method for the prevention of mastitis in lactating cows by intramuscular injection of Biferon-B at doses of 5.0–10.0–20.0 ml, provided a preventive effect in 25.0–75.0 % of animals; the best effect was achieved with Biferon-B at a dose of 5.0 ml. The use of Biferon-B in clinically healthy lactating animals was accompanied by a decrease in blood levels of stab neutrophils by 58.8–65.0 %, circulating immune complexes by 23.4–62.6 %, with a higher content of segmented neutrophils by 4.8–7.8 %, monocytes by 5.6–57.1 %, lymphocytes by 4.9–12.3 %, total immunoglobulins by 5.7–14.3 %, bactericidal and lysozyme activity of blood serum by 6.4–23.1 % and 4.3–13.7 %, respectively. The phagocytic activity of neutrophils decreased by 5.6–10.9 %. With lower indicators of the intoxication index dropped by 12.8–19.1 %, the content of average molecular peptides by 2.4–22.6 %, nitric oxide by 24.5–45.4 %, MDA by 2.8–36.7 %; catalase activity increased by 2.7–12.8 % and GPx by 10.4–29.7 %.
The objective of this study was to determine the therapeutic efficacy of the drug "Submastin-Cattle" in the treatment of subclinical mastitis in cattle. The trials were carried out on cows with subclinical mastitis on the farms of the Voronezh region. The animals were divided into two groups on the principle of analogies. The cows of the first group were treated with "Submastin-Cattle" twice at a dose of 10 ml with an interval of 24 hours. The animals of the second group (control) received placenta denatured emulsified (PDE) as required by the product direction. It has been found that the use of the drug "Submastin-Cattle" allows to achieve 83.6% of therapeutic efficacy, which is by 16.0% higher than when using PDE.
In this research, we studied the potential mutagenic and toxic effects of the drug Submastin-KRS, which contains a mixture of species-specific bovine recombinant cytokines and vitamin A as active ingredients, on the body of white laboratory outbred mice (n=48). The animals were divided into 8 groups, 6 individuals in each one. A single injection of Submastin-KRS at a therapeutic and high dose (1/10 of LD50) did not lead to a statistically significant increase in the frequency of polymorphonuclear erythrocytes (PCE) with micronuclei and a decrease in the proportion of PCE in the bone marrow of the mice. The combined administration of Submastin-KRS and experimental mutagens (dioxidin, mitomycin C) it also caused neither potentiation of mutagenic activity nor a decrease in the frequency of PCE with micronuclei. Fourfold administration of Submastin-KRS at a high dose with an interval of 24 hours before the injection of mitomycin C had an antitoxic effect that was expressed in a statistically significant increase in the proportion of PCE in the bone marrow, relative to mice that received only mitomycin C. A similar administration of dioxidine together with Submastin-KRS did not lead to differences in the proportion of PCE relative to this indicator with the introduction of dioxidine alone. Thus, Submastin-KRS showed no mutagenic and toxic properties in relation to mouse bone marrow cells and also had an antitoxic effect in mitomycin-induced suppression of hematopoiesis that may serve as the evidence of its safety.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.